Literature DB >> 8351693

[Quality of life and migraine. Validation of the QVM questionnaire in hospital consultation and in general medicine].

A Richard1, P Henry, G Chazot, H Massiou, S Tison, R Marconnet, A Chicoye, H d'Allens.   

Abstract

The feasibility, the validity and reliability of the questionnaire "Qualité de Vie et Migraine" (QVM) were assessed during a study performed on 107 patients recruited either in neurological departments in hospitals (N = 58) or by G.P. (N = 49). The study was designed as a Test-Retest, the self-questionnaire being filled twice at an interval of one week. The filling-in time was an average 7 min in hospital and 11 min for G.P.'s patients. The missing values were quite rare, between 1% and 2%. The items were assessed "very interesting" or "interesting" by 94% of the patients, and "easy" or "fairly easy to understand" by 96%. The principal component analysis performed on the whole sample allowed the extraction of 4 meaningful factors which were in agreement with the pre-defined structure of the questionnaire QVM. The 1st axis was a factor of psychological repercussion, the 2nd axis was a factor of functional and somatic repercussion, the 3rd axis was a factor of social repercussion and the 4th one was a factor of disturbance generated by the treatment. The QVM questionnaire allowed the calculation of a global index of quality of life and indexes according to the multifactorial structure. The global index was significantly higher for the most severe patients recruited in hospital, which means that the repercussion of migraine on quality of life was greater than for G.P.'s patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8351693

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  9 in total

Review 1.  Burden of migraine. A review of its socioeconomic impact.

Authors:  G D Solomon; K L Price
Journal:  Pharmacoeconomics       Date:  1997       Impact factor: 4.981

2.  The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care.

Authors:  André Pradalier; Michel Lantéri-Minet; Gilles Géraud; Hervé Allain; Christian Lucas; Antonio Delgado
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 3.  [Socio-economic impact of migraine and headaches in France].

Authors:  Jean-Paul Auray
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study.

Authors:  André Pradalier; Jean-Paul Auray; Abdelkader El Hasnaoui; Kazem Alzahouri; Jean-François Dartigues; Gérard Duru; Patrick Henry; Michel Lantéri-Minet; Christian Lucas; Guy Chazot; Anne-François Gaudin
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

5.  The Development and Psychometric Properties of the MSQOL: A Migraine-Specific Quality-of-Life Instrument.

Authors:  S P McKenna; L C Doward; K M Davey
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 6.  [Tools for assessing patient perception of the impact of migraine].

Authors:  Abdelkader El Hasnaoui; Adam Doble; Anne-Françoise Gaudin
Journal:  CNS Drugs       Date:  2006       Impact factor: 6.497

7.  The Levels of Circulating Proangiogenic Factors in Migraineurs.

Authors:  Slawomir Michalak; Alicja Kalinowska-Lyszczarz; Danuta Wegrzyn; Anna Thielemann; Krystyna Osztynowicz; Wojciech Kozubski
Journal:  Neuromolecular Med       Date:  2017-09-16       Impact factor: 3.843

8.  Increased Serum CD14 Level Is Associated with Depletion of TNF-α in Monocytes in Migraine Patients during Interictal Period.

Authors:  Slawomir Michalak; Alicja Kalinowska-Lyszczarz; Danuta Wegrzyn; Adam Niezgoda; Jacek Losy; Krystyna Osztynowicz; Wojciech Kozubski
Journal:  Int J Mol Sci       Date:  2017-02-13       Impact factor: 5.923

9.  A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study.

Authors:  Angèle Guilbot; Marie Bangratz; Samira Ait Abdellah; Christian Lucas
Journal:  BMC Complement Altern Med       Date:  2017-08-30       Impact factor: 3.659

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.